Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Feb 08, 2026
BSX vs MDT vs SYK: MedTech Earnings Preview as Q4 Results Put Growth and Margins in Focus

BSX vs MDT vs SYK: MedTech Earnings Preview as Q4 Results Put Growth and Margins in Focus

Key Takeaways

  • Boston Scientific (BSX) reports Q4 2025 earnings on February 4, with consensus expecting $0.78 adjusted EPS on $5.27B revenue, in line with guidance of $0.77–$0.79 EPS and 11–13% organic growth.

  • Medtronic (MDT) posted strong Q2 FY26 results: $9B revenue (+5.5% organic), $1.36 adjusted EPS, raising FY26 guidance amid pulsed field ablation momentum. Q3 FY26 results are expected February 17.

  • Stryker (SYK) delivered record Q4/FY 2025 results: $7.17B Q4 revenue (+11% organic), $4.47 adjusted EPS; FY sales topped $25B with 2026 guidance of 8–9.5% organic growth.

  • BSX leads in cardiovascular and MedSurg growth, while MDT and SYK focus on stable margins and capital equipment strength.

  • All three benefit from procedural volume recovery, though tariff headwinds (~$185–$400M impact) loom for 2026.

  • Investor focus: BSX’s strong beat history (~7% average) vs. peers’ raised outlooks signals competitive positioning.

Why This Comparison Matters

Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.

MDT’s ablation surge and SYK’s Mako robotics dominance illustrate trade-offs between growth and scale. Combined, the trio represents ~$300B in market capitalization, offering investors insight into cardiovascular, orthopedics, and surgical trends amid 8–10% industry growth forecasts.

BSX Earnings Focus

  • Revenue: $5.27B (+15.6% YoY, 11–13% organic per guidance)

  • Adjusted EPS: $0.78 (+11% YoY), within company guidance of $0.77–$0.79

  • Key drivers:

    • Cardiovascular (~65% revenue): FARAPULSE PFA, WATCHMAN FLX

    • MedSurg: Neuromodulation post-Axonix

    • U.S. revenue: ~$3.39B expected (+17%)

  • Other metrics: Margin pressure from tariffs, historical EPS beats ~7.36% average, FY25 EPS raised to $3.02–$3.04

  • Stock reaction: Historically +3–4% on positive surprises

MDT Earnings/Business Context

  • Q2 FY26 results: $9B revenue (+5.5% organic), $1.36 adjusted EPS (+8%)

  • Cardiac ablation: 71% growth (U.S. PFA +128%)

  • FY26 guidance: 5.5% organic revenue growth, EPS $5.62–$5.66

  • Margins: Adjusted gross margin +70bps to 65.9%

  • Risks: Tariff impacts (~$185M FY26), China VBP pressures

  • Outlook: Scale and diversification provide stability vs. BSX’s higher-growth trajectory

SYK Earnings/Business Context

  • Q4/FY 2025 results: $7.17B Q4 revenue (+11% organic), $4.47 adjusted EPS (+11.5%); FY $25.12B revenue (+10.3% organic), $13.63 EPS (+11.8%)

  • Margins: Adjusted operating margin +100bps to 26.3%; free cash flow 81% of adjusted net earnings

  • 2026 guidance: 8–9.5% organic growth, $14.90–$15.10 EPS

  • Drivers: Mako robotics (orthopedics), double-digit MedSurg/Neuro growth, vascular pressures manageable

  • Risks: Tariffs (~$400M), supply chain, orthopedics competition

  • Positioning: Procedural and capital equipment focus contrasts BSX’s interventional emphasis

AI Trading Bot Perspective

Tickeron offers AI-driven trading bots for BSX, MDT, and SYK:

  • BSX bot: Trend Trader for Broad Market Optimal Financial Fusion (60min FA), targeting large-cap trend momentum

  • MDT bot: Corridor TP-SL 2 AI Agent (60min), optimized for channel-based entries/exits

  • SYK bot: Trend Trader for Beginners (60min TA), ideal for orthopedic momentum plays

Historical performance varies by market conditions; these bots provide automated signals to complement manual analysis.

Key DriversCardio & MedSurgCardio & scaleOrtho/Capital equipment

  • BSX: High-growth cardiovascular, potential upside from historical beats

  • MDT: Broad therapy stability, slower growth but reliable margins

  • SYK: Ortho/surgical dominance with strong margin expansion

  • Risks: BSX procedure-sensitive; MDT China & tariffs; SYK supply/ortho competition

Investor sentiment tilts BSX for growth, peers for stability, reflecting trade-offs between upside potential vs. steady execution.

Tickeron AI Verdict

Tickeron’s AI models currently favor BSX pre-earnings, citing:

  • Superior trend stability

  • 15%+ organic trajectory

  • Historical EPS beat consistency

MDT and SYK provide lower-volatility, steady profiles, but BSX holds a probabilistic edge if guidance is reaffirmed and tariffs remain manageable.

Disclaimers and Limitations

Related Ticker: BSX, SYK, MDT

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


Momentum Indicator for BSX turns positive, indicating new upward trend

BSX saw its Momentum Indicator move above the 0 level on July 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

BSX moved above its 50-day moving average on July 31, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for BSX crossed bullishly above the 50-day moving average on August 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BSX advanced for three days, in of 334 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 345 cases where BSX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for BSX moved out of overbought territory on August 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 47 similar instances where the indicator moved out of overbought territory. In of the 47 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 67 cases where BSX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BSX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BSX broke above its upper Bollinger Band on August 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BSX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.928) is normal, around the industry mean (11.035). P/E Ratio (20.393) is within average values for comparable stocks, (70.949). Projected Growth (PEG Ratio) (0.724) is also within normal values, averaging (4.006). BSX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (3.575) is also within normal values, averaging (34.463).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.08B. The market cap for tickers in the group ranges from 1.86K to 201.83B. ABT holds the highest valuation in this group at 201.83B. The lowest valued company is CSAY at 1.86K.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -1%. For the same Industry, the average monthly price growth was 7%, and the average quarterly price growth was -7%. MODD experienced the highest price growth at 42%, while PFSA experienced the biggest fall at -62%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was 35%. For the same stocks of the Industry, the average monthly volume growth was 46% and the average quarterly volume growth was -12%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 74
Price Growth Rating: 57
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: -6 (-100 ... +100)
View a ticker or compare two or three
BSX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a maker of medical devices

Industry MedicalNursingServices

Profile
Details
Industry
Medical Specialties
Address
300 Boston Scientific Way
Phone
+1 508 683-4000
Employees
48000
Web
https://www.bostonscientific.com
Interact to see
Advertisement
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Copart (CPRT) is set to report fiscal Q2 2026 earnings on February 19, 2026, after market close. Consensus calls for EPS of $0.39–$0.40 and revenue of $1.15–$1.18 billion. Global Payments (GPN) posted Q4 2025 adjusted EPS of $3.18, in line with expectations, and adjusted net revenue of $2.32 billion, up 6% in constant currency (excluding dispositions). Thomson Reuters (TRI) delivered Q4 2025 adjusted EPS of $1.07 and revenue of $2.01 billion, up 5% year over year, supported by recurring subscription growth.
Unilever PLC (UL) leads year-to-date performance with a 12.61% gain, ahead of Diageo plc (DEO) at 9.90% and Keurig Dr Pepper Inc. (KDP) at 4.27%. DEO offers the highest dividend yield at 4.35%, compared with KDP (3.16%) and UL (2.97%). All three stocks carry low betas—DEO (0.18), UL (0.24), and KDP (0.35)—highlighting their defensive characteristics.
Q1 Fiscal 2026 Results: Revenue of $333M and adjusted EBITDA of $50M (15% margin), exceeding analyst expectations. FY2026 Guidance Raised: Adjusted EBITDA now projected at $225M, with revenue reaffirmed near $1.5B. EV Backlog Growth: 855 electric buses worth $277M, highlighting robust demand supported by EPA clean bus funding.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.
EDSA (Edesa Biotech) is up more than 21% today largely on speculative trading in a very illiquid penny stock with no clear, company‑specific news catalyst, likely driven by technical factors, retail flows, and short‑term trading rather than fundamentals.
Q4 2025 revenue came in strong at about 214–215 million, up mid‑30s percent year over year and a few percent above estimates, but GAAP EPS was only 0.08 versus expectations around 0.31, a roughly 70–75% miss and down from 0.13 a year earlier.
Estée Lauder Companies Inc. (EL) has rebounded with ~12% YTD gains and 50%+ one-year returns, supported by margin improvements and strong skincare/fragrance demand despite broader prestige beauty challenges.
BSX vs MDT vs SYK: MedTech Earnings Preview as Q4 Results Put Growth and Margins in Focus